This measure assesses the percentage of patients 18 years of age and older who received a least 180 treatment days of ambulatory medication therapy for a select therapeutic agent during the measurement year and at least one therapeutic monitoring event for the therapeutic agent in the measurement year. Report the following three rates and a total rate:
- Rate 1: Annual Monitoring for patients on angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB): At least one serum potassium and a serum creatinine therapeutic monitoring test in the measurement year.
- Rate 2: Annual monitoring for patients on diuretics: At least one serum potassium and a serum creatinine therapeutic monitoring test in the measurement year.
- Total rate (the sum of the two numerators divided by the sum of the two denominators)
Measure Specs
General Information
Numerator
This measure is reported as two rates and a total rate.
Rate 1: Annual monitoring for patients on ACE inhibitors or ARBs: the number of patients with at least one serum potassium and serum creatinine therapeutic monitoring test in the measurement year.
Rate 2: Annual monitoring for patients on diuretics: the number of patients with at least one serum potassium and serum creatinine therapeutic monitoring test in the measurement year.
Total rate: sum of the 2 numerators.
Denominator
Patients age 18 and older as of the end of the measurement year (e.g., December 31) who are on selected persistent medications (ACE Inhibitors/ARB or Diuretics.)
Exclusions
Exclude patients who use hospice services or elect to use a hospice benefit any time during the measurement year, regardless of when the services began.
Exclude patients who had an acute or nonacute inpatient encounter during the measurement year.
Measure Record
Point of Contact
© 2006 by the National Committee for Quality Assurance
1100 13th Street, NW, Suite 1000
Washington, DC 20005
Public Comments